Clinical Trials Browser

Phase 2 × tepotinib × 30 days × Clear all

NCT03940703 2026-02-27

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

Phase 2 Active not recruiting

140 enrolled 47 charts

Carcinoma, Non-Small-Cell Lung

NCT06106802 2026-02-23

Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment

Phase 2 Recruiting

Non-Small Cell Lung Cancer Metastatic